Advertisement

Einführung

  • Monika Christ
Chapter
  • 405 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL et al. (2002) Comparison of DNA-and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 20: 65–73CrossRefPubMedGoogle Scholar
  2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al. (2003) Average Risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 111–1130CrossRefGoogle Scholar
  3. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF (2000) Risk models for familial ovarian and breast cancer. Genet Epidemiol 18: 173–90.CrossRefPubMedGoogle Scholar
  4. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, Ponder BJ, Easton DF (2002) A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 86: 76–83.CrossRefPubMedGoogle Scholar
  5. Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister (Hrsg.) (2004) Krebs in Deutschland — Häufigkeiten und Trends. Saarbrücken, 4. Aufl.Google Scholar
  6. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802–10.PubMedGoogle Scholar
  7. Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance J Natl Cancer Inst 94: 1221–1226PubMedGoogle Scholar
  8. Bevilacqua G, Silingardi V, Marchetti P (2001) Exemestane for the prevention of breast cancer in postmenopausal unaffected carriers of BRCA1/2 mutations-Aromasin Prevention Study (Apres). Breast Cancer Res Treat. Special Issue: 24th Annual San Antonio Breast Cancer Symposium. 69: 226.Google Scholar
  9. Blue Cross and Blue shield association technology evaluation center (2003) Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer. Assessment program 18, No 15Google Scholar
  10. Breast cancer linkage consortium (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 349: 1505–10Google Scholar
  11. Breast cancer linkage consortium (1999) Cancer Risks in BRCA2 Mutation Carriers. J Natl Cancer Inst 91:1310–1316CrossRefGoogle Scholar
  12. Bundesministerium für Gesundheit und Soziale Sicherung (2004) Bekanntmachung des Bundesausschusses der Ärzte und Krankenkassen über eine Änderung der Richtlinien über die Früherkennung von Krebserkrankungen (Krebsfrüherkennungs-Richtlinien) vom 15. Dezember 2003. Bundesanzeiger Nr. 1 (S. 2) vom 3. Januar 2004Google Scholar
  13. Chang-Claude J (2003) BRCA1/2 and the prevention of breast cancer. In: Human Genetics Epidemiology, Ed. Khoury and Little, Oxford University PressGoogle Scholar
  14. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O et al. (2004) A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer N Engl J Med 350: 1081–1092CrossRefPubMedGoogle Scholar
  15. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators (2002): First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360: 817–24Google Scholar
  16. Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, et al. (2001): Ductal Lavage for Detection of Cellular Atypia in Women at High Risk for Breast Cancer. J Natl Cancer Inst 93: 1624–1632PubMedGoogle Scholar
  17. Del Tito BJ, Poff HE, Novotny M, Cartledge DM, Walker RI, Earl CD, Bailey AL (1998) Automated fluorescent analysis procedure for enzymatic mutation detection Clin Chem 44: 731–739PubMedGoogle Scholar
  18. Dunn BK, Ford LG (2000) Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT) European Journal of Cancer 36: 49–50Google Scholar
  19. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451–1467Google Scholar
  20. Easton DF, Bishop DT, Ford D, Crockford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer:results from 214 families. Am J Hum Genet 52: 678–701PubMedGoogle Scholar
  21. Engel J, Hölzel D, Kerr J, Schubert-Fritschle G (2003) Epidemiologie. In: Empfehlungen zur Diagnostik, Therapie und Nachsorge. Mammakarzinome. Hrsg Sauer HJ München: Zuckschwerdt 9. AuflageGoogle Scholar
  22. Engel J, Hölscher G, Schubert-Fritschle G (2004) Epidemiologie. In: Empfehlungen zur Diagnostik, Therapie und Nachsorge. Maligne Ovarialtumoren. Hrsg Schmalfeldt B München: Zuckschwerdt 7. AuflageGoogle Scholar
  23. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium Lancet 343: 692–695CrossRefPubMedGoogle Scholar
  24. Ford D, Easton DF, Stratton M et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA 1 and BRCA 2 genes in breast cancer families. Am J Hum Genet 62: 676–689CrossRefPubMedGoogle Scholar
  25. Foulkes WD, Metcalfe K, Sun P et al. (2004) Estrogen receptor status in BRCA1-and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10: 2029–34.PubMedGoogle Scholar
  26. Friedrich M (1998). MRI of the breast: state of the art. Eur. Radiol 8: 707–725CrossRefPubMedGoogle Scholar
  27. Frost MH, Schaid DJ, Sellers TA et al. (2000) Long-term satisfaction and psychological and social functioning following bilateral prophylactic surgery. JAMA 284: 319–324CrossRefPubMedGoogle Scholar
  28. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D. (1997) Variations of risks of breast and ovarian cancer associated with different germline mutations of the BRCA 2 gene. Nat Genet 15:103–105CrossRefPubMedGoogle Scholar
  29. Gayther SA, Warren W, Mazoyer S et al. (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11: 428–433CrossRefPubMedGoogle Scholar
  30. German consortium of hereditary breast and ovarian cancer (2002). Comprehensive Analysis of 989 Patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the german population. Int J Cancer 97: 472–480Google Scholar
  31. Giordano SH, Buzdan AU, Hortobagyi GN (2002) Breast cancer in men. Ann Int Med 137: 678–687PubMedGoogle Scholar
  32. Hamajima N, Hirose K, Tajima K et al. (2002) Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 9506 without the disease. Br J Cancer 87: 1234–45PubMedGoogle Scholar
  33. Harbeck N, Eiermann W, Engel J, Funke I, Janni W, Lebeau A, Permanetter W, Raab G, Untch M, Zemzoum I (2003) Prognostische und prädiktive Faktoren beim primären Mammakarzinom. In: Empfehlungen zur Diagnostik, Therapie und Nachsorge. Mammakarzinome. Hrsg Sauer HJ München: Zuckschwerdt 9. AuflageGoogle Scholar
  34. Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77–84CrossRefPubMedGoogle Scholar
  35. Hartmann LC, Sellers TA, Schaid DJ et al. (2001). Efficacy of bilateral mastectomy in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 93: 1633–1637CrossRefPubMedGoogle Scholar
  36. Hedenfalk I, Duggan D, Chen Y et al. (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344: 539–548CrossRefPubMedGoogle Scholar
  37. Heinig A, Beck R, Heywang-Köbrunner S, Kölbl H, Lampe D. (2002) Suppression of unspecific diffuse or focal enhancement on magnetic resonance imaging (MRI) of the breast by antiestrogen medication-first results. Tumori 88: 215–233PubMedGoogle Scholar
  38. Heywang-Köbrunner S, Schreer I (2003). Bildgebende Mammadiagnostik Thieme 2. Aufl.Google Scholar
  39. Heywang-Köbrunner SH, Brandt S, Amaya B et. al. (2002) Influence of short-term Exemestan treatment on contrast-enhanced (CE) breast MRI: study design and first experiences. Breast Cancer Res Treat 76(suppl 1) 610Google Scholar
  40. Holinski-Feder E, Brandau O, Nestle-Krämling C, Derakhshandeh-Peykar P, Murken J, Untch M,; Meindl A (1998). Genetik des erblichen Mammakarzinoms. Grundlagen-Forschung-Diagnostik Dtsch Ärztebl 95: 600–605Google Scholar
  41. Jernstrom H, Lerman C, Ghadirian P et al. (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2 Lancet 354:1846–1850CrossRefPubMedGoogle Scholar
  42. Kauff ND, Satagopan JM, Robson ME et al. (2002). Risk reducing salpingo-oophorectomy in women with BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609–1615CrossRefPubMedGoogle Scholar
  43. Key TJ, Allen NE, Verkasalo PK, Banks E (2001) Energy balance and cancer: the role of sex hormones Proceedings of the Nutrition Society 60: 81–89Google Scholar
  44. Kiechle M, Böttcher B, Ditsch N, Kuschel B, Plattner B, Schwarz-Boeger U, Untchh M, Vodermaier A. (2003) Hereditäres Mammakarzinom In Sauer H (Hrsg.) Mammakarzinome: Empfehlungen zur Diagnostik, Therapie und Nachsorge. München: Zuckschwerdt 9.Aufl.Google Scholar
  45. King MC, Wieand S, Hale K et al. (2001). Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABPP1) Breast Cancer Prevention Trial JAMA 286: 2251–2256PubMedGoogle Scholar
  46. Knippers (2001) Molekulare Genetik. 8. Auflage. Stuttgart: Thieme-VerlagGoogle Scholar
  47. Korkko J, Annunen S, Pihlajamaa T, Prockop DJ, Ala-Kokko L (1998) Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci U S A. 95: 1681–1685CrossRefPubMedGoogle Scholar
  48. Kriege M, Brekelmans CT, Boetes C et al. (2004) Efficacy of MRI and Mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351: 27–37CrossRefGoogle Scholar
  49. Kuhl CK, Schmutzler RK, Leutner CC, Kempe A, Wardelmann E, Hocke A, Maringa M, Pfeifer U, Krebs D, Schild HH. (2000) Breast MR imaging in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 215: 267–379PubMedGoogle Scholar
  50. Kuschel B, Anthuber C, Kiechle M, Untch M. (2004) Hereditäres Ovarialkarzinom. In: Schmalfeld B (Hrsg) Empfehlungen zur Diagnostik, Therapie und Nachsorge. Maligne Ovarialtumoren Zuckschwerdt 7. Aufl.Google Scholar
  51. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20: 2310–2318CrossRefPubMedGoogle Scholar
  52. Lakhani SR, Manek S, Penault-Llorca F et al. (2004) Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 10: 2473–81PubMedGoogle Scholar
  53. Luckey JA, Drossman H, Kostichka AJ, Mead DA, D’Cunha J, Norris TB, Smith LM (1990) High speed DNA sequencing by capillary electrophoresis Nucl Ac Res 18: 4417–4421Google Scholar
  54. Macoska J (2002) The progressing clinical utility of DNA Microarrays. CA Cancer J Clin 52: 50–59PubMedGoogle Scholar
  55. McDonnell SK, Schaid DJ, Myers JL et al. (2001) efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938–3943PubMedGoogle Scholar
  56. McGrath SB, Bounpheng M, Torres L, Calavetta M, Scott CB, Suh Y, Rines D, van Orsouw N, Vijg J. (2001) High-speed, multicolor fluorescent two-dimensional gene scanning. Genomics 78: 83–90.CrossRefPubMedGoogle Scholar
  57. Meijers-Heijboer H, van Geel B, van Putten WL et al. (2001). Breast cancer after prophylactic mastectomy in women with a BRCA 1 or BRCA 2 mutation. N Engl J Med 345:159–164CrossRefPubMedGoogle Scholar
  58. Metcalfe K, Lynch HT, Ghadirian P et al: (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, J Clin Oncol 22: 2328–2335CrossRefPubMedGoogle Scholar
  59. Miki Y, Swensen J, Shattuck-Eidens D et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266: 66–71PubMedGoogle Scholar
  60. Minckwitz G v. (2004) Prävention des Mammakarzinoms. Fakten, Daten, Visionen. Bremen: UniMed 1. Aufl.Google Scholar
  61. Minckwitz G v., Prieshof B, Hofman K, Jakisch CH, Paepke S, Torode J, Kaufmann M. (2002) Prävention mit Goserelin und Ibandronat bei prämenopausalen Frauen mit familiärem Mammakarzinomrisiko. Erste Erfahrungen mit der GISS-studie. Arch gynecol obstetr 26(suppl1):53Google Scholar
  62. Morrison P, Hodgson S, Haites N. (2002) Familial Breast and ovarian cancer. Genetics, screening and management. Cambridge University PressGoogle Scholar
  63. Müller C, Haworth A. (2001) Draft best practice guidelines for molecular analysis of hereditary breast and ovarian cancer. European moleculare genetics quality networkGoogle Scholar
  64. Narod SA, Risch H, Moslehi R et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339: 424–428CrossRefPubMedGoogle Scholar
  65. Narod SA, Sun P, Ghadirian P et al. (2001) Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357: 1467–1470PubMedGoogle Scholar
  66. Norberg T, Klaar S, Lindqvist L, Lindahl T, Ahlgren J, Bergh J. (2001) Enzymatic mutation detection method evaluated for detection of p53 mutations in cDNA from breast cancers. Clin Chem May 47: 821–8PubMedGoogle Scholar
  67. Orsouw van NJ, Dhandab RK, Elhajic Y, Narodc SA, Lid FP, Enge C, Vijga J (1999) A highly accurate, low cost test for BRCA1 mutations. J Med Genet 36: 747–753PubMedGoogle Scholar
  68. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. (1998). Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98–101PubMedGoogle Scholar
  69. Rebbeck TR, Levin AM, Eisen A et al. (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers J Natl Cancer Inst 91: 1475–1479CrossRefPubMedGoogle Scholar
  70. Rebbeck TR, Lynch HT, Neuhausen SL et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346: 1616–22.CrossRefPubMedGoogle Scholar
  71. Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14: 185–187CrossRefPubMedGoogle Scholar
  72. Roest PA, Roberts RG, Sugino S, van Ommen GJ, den Dunnen JT(1993) Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum Mol Genet 2: 1719–21PubMedGoogle Scholar
  73. Robson M (2000) Are BRCA1-and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer. J Clin Oncol 18:113s–118PubMedGoogle Scholar
  74. Sanger F, Nicklen S, and Coulson AR (1977) DNA sequencing with chain-terminating inhibitors Proc Natl Acad Sci U S A 74: 5463–5467Google Scholar
  75. Schmutzler R, Beckmann MW, Kiechle M. (2002) Prävention: familiäres Mamma-und Ovarialkarzinom. Dtsch Ärztebl 99: A–132Google Scholar
  76. Schmutzler R, Schlegelberger B, Meindl, A., Gerber, WD, Kiechle, M. (2003): Beratung, genetische Testung und Prävention von Frauen mit einer familiären Belastung für das Mamma-und Ovarialkarzinom. Zentralbl Gynakol 125: 494–506PubMedGoogle Scholar
  77. Steindorf K, Schmidt M, Kropp S, Chang-Claude J. (2003) Case-control study of physical activity and breast cancer risk among premenopausal woman in Germany. Am J Epidemiol 157: 121–130CrossRefPubMedGoogle Scholar
  78. Strachan T, Read AP (1996): Molekulare Humangenetik. Heidelberg, Berlin, Oxford: Spektrum, Akademischer VerlagGoogle Scholar
  79. Thompson D, Easton D (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers Am J Hum Genet 68: 410–419CrossRefPubMedGoogle Scholar
  80. Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers J Natl Cancer Inst 94: 1358–1365PubMedGoogle Scholar
  81. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE. (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13: 117–119CrossRefPubMedGoogle Scholar
  82. Verbundprojekt Familiärer Brust-und Eierstockkrebs der Deutschen Krebshilfe (2004a): Zwischenbericht der 11 Zentren in der Auslaufförderung. Deutsche Krebshilfe, Unveröffentlichtes Dokument.Google Scholar
  83. Verbundprojekt Familiärer Brust-und Eierstockkrebs der Deutschen Krebshilfe (2004b): Kurzleitlinie zur Identifikation und Versorgung von Frauen mit einer familiä-ren Belastung für Brust-und Eierstockkrebs im Rahmen der Regelversorgung. Unveröffentlichtes Dokument.Google Scholar
  84. Verhoog LC, Brekelmans CT, Seynaeve C et al.(1999) Survival in Hereditary Breast Cancer Associated With Germline Mutations of BRCA2. J Clin Oncol 17: 3396–3402PubMedGoogle Scholar
  85. Verhoog LC, Brekelmans CTM, Seynaeve C, Meijers-Heijboer EJ, Klijn JGM. (2000) Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83: 384–386CrossRefPubMedGoogle Scholar
  86. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women Lancet 352: 93–97PubMedGoogle Scholar
  87. Warner E, Plewes DB, Shumak RS et al. (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19: 3524–31PubMedGoogle Scholar
  88. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2 Nature 378: 789–792CrossRefPubMedGoogle Scholar
  89. Wyshak G, Frisch RE (2000) Breast cancer among former college athletes compared to non-athletes: a 15-year follow-up Br J Cancer 82: 726–730PubMedGoogle Scholar
  90. Xiao W, Oefner HP (2001). Denaturing high-performance liquid chromatography: a review. Hum Mut 17: 439–474PubMedGoogle Scholar
  91. Zion SM, Slezak JM, Sellers TA, Woods JE, Arnold PG, Petty PM, Donohue JH, Frost MH, Schaid DJ, Hartmann LC (2003) Reoperations after prophylactic mastectomy with or without implant reconstruction Cancer 98: 2152–2160CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2005

Authors and Affiliations

  • Monika Christ
    • 1
  1. 1.Heidelberg

Personalised recommendations